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Abstract 
Background: Cervical cancer is the fourth most common cancer in incidence and the first genital cancer in women 
around the world, which 95% of them are related to human papillomavirus (HPV) infections. The risk of cervical 
cancer increases 10-12 time in women with HPV infection. This study aim to evaluate the prevalence of high-risk 
HPV infections among 15-45 years old women.   
Materials and Methods: This cross sectional study was carried out on 92 normal women who admitted at Semnan 
hygiene center and has 15-45 years old. Cervical samples were collected using Cytobrush cell collector and 
consequently DNA extraction was performed using commercial DNA extraction kit. Polymerase Chain Reaction 
(PCR) was done using HPV (GP5, GP6) universal primers accompanied by positive and negative control in each 
PCR run. In order to extracted DNA template quality control, actin gene used as housekeeping gene.  
Results: In this investigation, study subjects age range found to be 15-45 with mean of 30±0.9 years old. HPV 
infection was not found in patient group. Thus, further approach in order to HPV16 and HPV18 types detection, was 
not performed. However, other studies represented low to moderate prevalence for HPV in some regions of Iran.  
Conclusion: Cervical cancer is one the major health concern and the fourth most common cancer around the world. 
This cancer is more common in developing countries than developed countries due to lack of screening program. 
Regard to possible high prevalence rate of HPV virus and its association with cervical cancer, we suggest further 
determination of the HPV prevalence as well as planning in large-scale vaccination in high risk group. 
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Regard to WHO report, cervical cancer is the 
fourth most common cancer among women and 
seventh most prevalent cancer among world’s human 
population (1).  Numerous studies has been reported 
that HPV is the first and most important agent 
causing cervical cancer (2, 3).Translatable HPV 
genome enters host cells and this process is necessary 
for creating and growth malignancy in those cells 
(4).The carcinogenicity of HPV is attributing to E6 
and E7 viral gene which theirs modifier proteins 
interferes with P53 and Rb tumor suppressor proteins 
(5-7). In addition, E2 viral gene silencing is another 
factor for progress in HPV associated cervical cancer 
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malignancy (8). Knowledge on HPV association with 
High-grade squamous intraepithelial lesions and 
cervical cancer as well as pre-invasive lesion 
potential ability has been justify performing  
investigations on screening and treatment programs 
for further eliminating this viral infection (9). 
Cervical intraepithelial neoplasia (CIN) categorized 
to 3 different clinical stage follow as: CIN I as slight 
dysplasia, CIN II as moderate and CIN III as sever 
dysplasia (10). 
The maximum incidence rate of cervical 
epithelial cells dysplasia is up to 35 years of age 
but the 45 is the second peak(11). The prevalence 
rate for cervical cancer found to be high in 
developing countries owing to lack of or weakness in 
screening program.  
More than 82 percent of cervical cancer is in 
developed countries as well as more than 91 percent 
is in developing countries are associated with HPV 
(7). HPV genome existence in all degree of cervical 
cancer has been confirmed and women with HPV 
have several times increased risk for cervical cancer 
(12). Fifteen serotype are associated with cervical 
cancer out of 118 HPV known serotype (13,14). 
Some of these serotype including 
16,18,31,33,39,45,51,52,56,58,59,68,73,82 HPV 
serotypes contributed to cause 90 percent of high 
grade CIN  and cervical cancer (15). 
 HPV16 and HPV18 are most frequent 
serotype, which contributed to invasive cancer as 
well as CIN II and CIN III and found in 70 percent of 
women with these diseases (16,17). HPV 16 has been 
found in 75 percent of cervix, Vulva and anus 
carcinoma (18) and also is most common HPV 
serotype in women with normal cervical cytology 
(16, 17). HPV 16 and 18 attribute to 87 percent of 
invasive cervical cancer (ICC), 89 percent of 
squamous cell carcinoma (SCC) and 84 percent of 
high grade intraepithelial lesion (HSIL). Among theme 
HPV16 cause 56%, 55% and 45%  and HPV 18 cause 
about 17%, 12% and 6% of those diseases respectively 
however these amounts is somewhat variable depend 
on geographic location (19). Risk of transmission 
through sexual contact is high in women (20-24). 
Many studies has been shown that existence of  
screening program for cervical cancer using 
conventional or PCR method can decrease morbidity 
and mortality in women specially women more than 
30 years old (25). With respect to clinical importance 
of HPV specially types 16 and 18, this investigation 
aim to determine the prevalence rate for HPV 16 and 
18 types in 92 normal Iranian women.  
Methods 
Patient and sample. In this study, 92 normal 
Iranian women who admitted to Semnan hygiene 
center were included. Study subjects age range was 
between 15-45 years. Cervical sample were collected 
using sterile Cytobrush cell collector according to 
standard protocol. Consequently, samples stored at -
20ºC until subsequent use. In addition, ethical 
approval and study subjects consent were obtained and 
recorded in theirs medical records.     
DNA extraction. In order to DNA extraction, 
the samples blended with 3 ml normal saline and 
centrifuge at 3000 g for 3 minutes twice. Supernatant 
discarded and the pellet used for subsequent extraction 
procedure. DNA extraction was performed using high 
yield DNA purification Kit (CinnaGen Molecular 
Biology and Diagnostic, Iran) according to the 
manufacturer instruction. Extracted DNA was 
evaluated by electrophoresis on 1% agarose gel. 
 
Table1: Primers name and sequences. 
Primer Name Primer Sequence Amplicon size (bp) 
ß-ACTIN Forward: GTGGGGCGCCCCAGGCACCA 
Reverse: CTCCTTAATGTCACGCACGATTTC  
535 
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Polymerase chain reaction:  
1. Housekeeping gene. In order to DNA 
template quality control, Actin gene was used as 
housekeeping gene. PCR performed by Eppendorf 
thermal cycler, using specific primer against Actin 
gene (Table 1). Thermal cycling program was follow 
as :   94º C for 2 min followed by 25 cycles of 94º C 
for 30 sec, 60º C  for 30 sec, 72º C for 30 sec and 
final extension at 72º C  for 7 minutes. Eventually, 
5μl of PCR product load into 1% agarose gel (Roche- 
Basel- Switzerland) with TAE 1X running buffer, 
then stained by GelRed and analyze by Gel 
Documentation System Transilluminator® (Thermo 
Fisher.  USA) 
3. PCR for HPV detection. Polymerase chain 
reaction was performed for each extracted DNA 
template using GP5 and GP6 universal primers 
against highly conserve HPV gene (table 1), (26). 
The thermal-cycling program  was the Initial 
denaturation at 94º C for 5 min followed by 35 cycles 
of 94º C for 60 sec, 55º C  for 60 sec, 72ºC for 40 sec 
and final extension at 72ºC  for 10 minutes. In 
addition, positive and non-template control was used 
in each run then 5μl of PCR product load into 1% 
agarose gel beside 100bp DNA ladder and visualize 
by UV transiluminator®. 
Results 
In this investigation age range of the study 
subjects was between 15-45years with mean age of 
30±0.9. Almost half of them were 25-35 years old 
(Figure 1). PCR was performed on extracted DNA 
using specific primer against actin gene and the result 
was excellent and represented the presence of actin 
gene in all samples (Figure 2). In addition, PCR 
carried out on extracted DNA using HPV specific 
primers. There was no positive sample for HPV 
among study subjects so PCR wasn’t perform for 
HPV (types 16 and 18) detection. PCR accuracy 
confirmed by positive and negative (non-template) 
controls (Figure 3). 
Discussion 
Cervical cancer is one of the most common 
cancer in term of incidence rate and cause of 
morbidity. According to WHO  report, 528000 of 
new cervical cancer case has been diagnosed in 2012 
around the world, which 85% of them were in 
developing countries (1). Regard to previous studies, 
the risk factors for cervical cancer were included: 
 
 
Figure 1. Age range distribution among study subjects. 
 
 
Figure 2. line 1-4 actin gene DNA amplification product on 
1% agarose gel electrophoresis, line 5, 100 bp DNA ladder, 
line 6 non template control. 
 
 
Figure 3. HPV DNA amplification, line 1 100bp DNA ladder, 
line 2 positive control, line 3-6: PCR on sample from study 
subjects. 1% Agarose gel electrophoresis with 1X TAE running 
buffer was used for gel electrophoresis. 
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having young age at first sexual contact, history of 
Chlamydia or herpes simplex infection, smoking, 
immune system failure, multiple sexual partner, 
familial background, having oral contraceptive pills 
and HPV infection (27, 28). Approximately, 95% of 
cervical cancer related to high risk HPVs. In endemic 
area, at least 80% of women infected by HPV until 
50 years old. In general, about 14-35% of women 
infected by HPV viruses but 80-90% of them were 
recovered within 2 years (29). 
This investigation aim to determine the 
prevalence rate for high risk HPV included type 16 
and 18 among 15-45 Iranian women in Semnan 
province. Our study illustrated that there was no 
infected individuals who infected by HPV.    
A Canadian study in 2000, determine 
prevalence rate for HPV among 1004 high risk 
women whom had 15-49 years old using Hybrid 
Capture II (HCII) ,PCR and genotyping methods and 
found the prevalence of 24% for HPV among 20-24 
years women (30). In this study, sample number has 
been very much more than our study and they use 
combined test for HPV detection. With respect to 
mentioned reasons and existence of some risk factors 
in theirs study group as well as religious beliefs and 
social behaviors of people in Semnan province, our 
result is reasonable and justified.  
A study in 2003 on 22089 women with age 
range of 20-90 years represented the prevalence rate 
of 5.2 % for HPV among them and the selected 
method was Pap smear (31). Sample size in our study 
was much lower than their study and age range was 
narrower either. For example most of them were 45% 
were 35-45 and 30% 15-25 years old, respectively.  
In an investigation by Tarkowski on 312 girls 
who has mean of 16 years old with history of 2 years 
sexual activity and 4 different sexual partners, the 
prevalence of HPV found to be 64% using PCR 
method (32). 
In another study was performed by Altugu in 
Turkey, HPV prevalence evaluated among 148 
women with pyrogenic endocervicitis using HC II 
method showed to be 5.4%. About 40 % and 16.2% 
of them had been using intrauterine devices (IUD) 
and oral contraceptive, respectively (33). 
A study in Argentina showed the prevalence 
of 43% and 60% for HPV in rural and Guarani 
Indians women respectively using PCR which had 
been associated with the age in firs sexual contact, 
number of sexual partner and smoking (34). 
In a study by Bagheri et al, in Tajrish hospital 
located in Tehran, Iran, showed prevalence of 36.5% 
and 5% for HPV among 59 patients with transitional 
cell carcinoma and 20 normal individuals respectively. 
The patients’ age was from 18-81 years and method 
for detection was PCR method (35). High prevalence 
in this study in patients group may due to increase in 
HPV copy number by the time. Only one sample (5%) 
in the control group was positive (35). 
A study in Shiraze city, Iran, on 101 women 
with cervical cancer, evaluated the prevalence of HPV 
using PCR method and found to be 87% among them 
(36). 
In another study in Tehran, Iran, on 851 women 
who has 18-65  years, the prevalence of HPV showed 
to be 31.1%  using Pap smear, PCR and RFLP which 
7.3% and 2.8% of them are type 16 and 18 HPV 
respectively (2). 
Our result disagreement with other studies may 
be owing to difference in sample size, age range and 
theirs risk factor for HPV as well as religious beliefs 
and social behaviors. 
Conclusion 
In conclusion with respect to  HPV clinical  
importance and high prevalence in some area of Iran, 
we suggest performing further investigation on 
determining exact prevalence of HPV in Iran for 
eliminating and early treatment of this disease . In 
addition, we suggested large-scale vaccination for 
HPV in high risk group in Iran.   
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